Differential patterns of allelic loss in estrogen receptor-positive infiltrating lobular and ductal breast cancer

Genes Chromosomes and Cancer

Volumn 47, Issue 12, 2008, Pages 1049-1066

  Loo, L W M ^a   Ton, C ^a   Wang, Y W ^a   Grove, D I ^a   Bouzek, H ^a   Vartanian, N ^a   Lin, M G ^a   Yuan, X ^a   Lawton, T L ^b   Daling, J R ^a   Malone, K E ^a   Li, C I ^a   Hsu, L ^a   Porter, Peggy L ^a,b  

^a Fred Hutchinson Cancer Research Center   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DNA; ESTROGEN RECEPTOR;

ADULT; AGED; ALLELE; ARTICLE; BREAST CANCER; CANCER DIAGNOSIS; CELL SELECTION; CHROMOSOME; CHROMOSOME 11Q; CHROMOSOME 16Q; CHROMOSOME 17P; CHROMOSOME 20P; CHROMOSOME 20Q; CHROMOSOME 3P; CHROMOSOME 5Q; CHROMOSOME 8P; CHROMOSOME 9P; COMPARATIVE STUDY; CONTROLLED STUDY; DNA CONTENT; DNA EXTRACTION; FLOW CYTOMETRY; GENE CLUSTER; GENE FREQUENCY; GENE IDENTIFICATION; GENE MAPPING; GENOMICS; HETEROZYGOSITY LOSS; HISTOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MITOSIS; NUCLEOTIDE SEQUENCE; PHENOTYPE; PRIORITY JOURNAL; SHORT TANDEM REPEAT; SINGLE NUCLEOTIDE POLYMORPHISM; TUMOR VOLUME; UNINDEXED SEQUENCE;

BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, LOBULAR; CASE-CONTROL STUDIES; DNA, NEOPLASM; FEMALE; GENE EXPRESSION PROFILING; HUMANS; IMMUNOHISTOCHEMISTRY; LOSS OF HETEROZYGOSITY; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTORS, ESTROGEN; TISSUE ARRAY ANALYSIS;

EID: 57149093413     PISSN: 10452257     EISSN: 10982264     Source Type: Journal    
DOI: 10.1002/gcc.20610     Document Type: Article

References (51)

1. Anbazhagan R, Fujii H, Gabrielson E. 1998. Allelic loss of chromosomal arm 8p in breast cancer progression. Am J Pathol 152:815-819.
2. Andersen J, Poulson H. 1989. Immunohistochemical estrogen receptor determination in paraffin embedded tissue. Cancer 64:1901-1908.
3. Ando Y, Iwase H, Ichihara S, Toyoshima S, Nakamura T, Yamashita H, Toyama T, Omoto Y, Karamatsu S, Mitsuyama S, Fujii Y, Kobayashi S. 2000. Loss of heterozygosity and microsatellite instability in ductal carcinoma in situ of the breast. Cancer Lett 156:207-214.
4. Arpino G, Bardou V, Clark G, Elledge R. 2004. Infiltrating lobular carcinoma of the breast: Tumor characteristics and clinical outcome. Breast Cancer Res Epub 6:R149-R156.
5. Banik S, Counter C. 2004. Characterization of interactions between PinX1 and human telomerase subunits hTERT and hTR. J Biol Chem 279:51745-51748.
6. Berx G, Cleton-Jansen A, Nollet F, de Leeuw W, van de Vijver M, Cornelisse C, van Roy F. 1995. E-cadherin is a tumour/invasion suppressor gene mutated in human lobular breast cancers. EMBO 14:6107-6115.
7. Buerger H, Otterbach F, Simon R, Schafer K, Poremba C, Diallo R, Brinkschmidt C, Dockhorn-Dworniczak B, Boecker W. 1999. Different genetic pathways in the evolution of invasive breast cancer are associated with distinct morphological subtypes. J Pathol 189:521-526.
8. Carter S, Negrini M, Baffa R, Gillum D, Rosenberg A, Schwartz G, Croce C. 1994. Loss of heterozygosity at 11q22-q23 in breast cancer. Cancer Res 54:6270-6274.
9. Chen C, Weiss N, Newcomb P, Barlow W, White E. 2002. Hormone replacement therapy in relation to breast cancer. JAMA 287:734-741.
10. Chen L, Huang S, Lee L, Davalos A, Schiestl R, Campisi J, Oshima J. 2003. WRN, the protein deficient in Werner syndrome, plays a critical structural role in optimizing DNA repair. Aging Cell 2:191-199.
11. Cristofanilli M, Gonzalez-Angulo A, Sneige N, Kau S, Broglio K, Theriault R, Valero V, Buzdar A, Kuerer H, Buccholz T, Hortobagyi G. 2005. Invasive lobular carcinoma classic type: Response to primary chemotherapy and survival outcomes. J Clin Oncol 23:41-48.
12. Deng G, Lu Y, Zlotnikov G, Thor A, Smith H. 1996. Loss of heterozygosity in normal tissue adjacent to breast carcinomas. Science 274:2057-2059.
13. Devilee P, Cornelisse C. 1994. Somatic genetic changes in human breast cancer. Biochim Biophys Acta 1198:113-130.
14. Elston C, Ellis I. 1991. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: Experience from a large study with long-term follow-up. Histopathology 19:403-410.
15. Fridlyand J, Snijders A, Ylstra B, Li H, Olshen A, Segraves R, Dairkee S, Tokuyasu T, Ljung B, Jain A, McLennan J, Ziegler J, Chin K, Devries S, Feiler H, Gray J, Waldman F, Pinkel D, Albertson D. 2006. Breast tumor copy number aberration phenotypes and genomic instability. BMC Cancer 6:96-103.
16. Fujii H, Szumel R, Marsh C, Zhou W, Gabrielson E. 1996. Genetic progression, histological grade, and allelic loss in ductal carcinoma in situ of the breast. Cancer Res 56:5260-5265.
17. Giri D, Goepel J, Rogers K. 1988. Immunohistological demonstration of progesterone receptor in breast carcinomas: Correlation with radioligand binding assays and oestrogen receptor immunohistology. J Clin Pathol 41:444-447.
18. Glogovac J, Porter P, Banker D, Rabinovich P. 1996. Cytokeratin labeling of breast cancer cells extracted from paraffin embedded tissue for bivariate flow cytometric analysis. Cytometry 24:260-267.
19. Gunther K, Merkelbach-Bruse S, Amo-Takyi BK, Handt S, Schroder W, Tietze L. 2001. Differences in genetic alterations between primary lobular and ductal breast cancers detected by comparative genomic hybridization. J Pathol 193:40-47.
20. Harris J, Lippman M, Veronesi U, Willit W. 1992. Breast Cancer (1). N Engl J Med 327:319-328.
21. Harris M, Howell A, Chrissohou M, Swindell RI, Hudson M, Sellwood R. 1984. A comparison of the metastatic pattern of infiltrating lobular carcinoma and infiltrating duct carcinoma of the breast. Br J Cancer 50:23-30.
22. Hsu S, Raine L, Fanger H. 1981. Use of biotin-avidin-peroxidase conplex (ABC) in immunoperoxidase techniques: A comparison between ABC and unlabeled antibody techniques. Am J Clin Pathol 75:816-821.
23. Hwang E, Nynte S, Chen Y, Moore D, Devries S, Korkola J, LJ E, Waldman F. 2004. Clonality of lobular carcinoma in situ and synchromus invasive lobular carcinoma. Cancer 100:2562-2572.
24. Jackson J, Pereira-Smith O. 2006. Primary and compensatory roles for RB family members at cell cycle gene promoters that are deacetylated and downregulated in doxorubicin-induced senescence of breast cancer cells. Mol Cell Biol 26:2501-2510.
25. Jaiswal A, Balusu R, Narayan S. 2005. Involvement of adenomatous polyposis coli in colorectal tumorigenesis. Front Biosci 10:1118-1134.
26. Kondo T, Oue N, Mitani Y, Kuniyasu H, Noguchi T, Kuraoka K, Nakayama H, Yasui W. 2005. Loss of heterozygosity and histone hypoacetylation of the PINX1 gene are associated with reduced expression in gastric carcinoma. Oncogene 24:157-164.
27. Korkola J, DeVries S, Fridlyand J, Hwang E, Estep A, Chen Y, Chew K, Dairkee S, Jensen R, Waldman F. 2003. Differentiation of lobular versus ductal breast carcinomas by expression microarray analysis. Cancer Res 63:7167-7175.
28. Lee J, Yannone S, Chen D, Povirk L. 2003. Requirement for XRCC4 and DNA ligase IV in alignment-based gap filling for nonhomologous DNA end joining in vitro. Cancer Res 63:22-24.
29. Li C, Anderson B, Daling J, Moe R. 2003a. Trends in incidence rates of invasive lobular and ductal breast carcinoma. JAMA 289:1421-1424.
30. Li C, Malone K, Porter P, Weiss N, Tang M, Cushing-Haugen K, Daling J. 2003b. Relationship between long durations and different regimens of hormone therapy and risk of breast cancer. JAMA 289:3254-3263.
31. Li C, Malone K, Porter P, Lawton T, Voigt L, Cushing-Haugen K, Lin M, Yuan X, Daling J. 2008. Relationship between menopausal hormone therapy and risk of ductal, lobular, and ductal-lobular breast carcinomas. Canc Epidemiol Biomarkers Prev 17:43-50.
32. Lin M, Wei L, Sellers W, Lieberfarb M, Wong W, Li C. 2004. dChipSNP: Significance curve and clustering of SNP-array-based loss-of-heterozygosity data. Bioinformatics 20:1233-1240.
33. Loo L, Grove D, Neal C, Williams E, Cousens L, Schubert E, Holcomb I, Massa H, Glogovac J, Li C, Malone K, Daling J, Delrow J, Trask B, Hsu L, Porter P. 2004. Array comparative genomic hybridization analysis of genomic alterations in breast cancer subtypes. Cancer Res 64:8541-8549.
34. Mersin H, Yildirim E, Gulben K, Berberoglu U. 2003. Is invasive lobular carcinoma different from invasive ductal carcinoma. Eur J Surg Oncol 29:390-395.
35. O'Connell P, Pekkel V, Fuqua S, Osborne C, Clark G, Allred D. 1998. Analysis of loss of heterozygosity in 399 premalignant breast lesions at 15 genetic loci. J Natl Cancer Inst 90:697-703.
36. Olshen A, Venkatraman E, Lucito R, Wigler M. 2004. Circular binary segmentation for the analysis of array-based DNA copy number data. Biostatistics 5:557-572.
37. Page D, Anderson T. 1987. Diagnostic Histopathology of the Breast. Edinburgh: Churchill Livingston.
38. Petermann E, Maya-Mendoza A, Zachos G, Gillespie D, Jackson D, Caldecott K. 2006. Chk1 requirement for high global rates of replication fork progression during normal vertebrate S phase. Mol Cell Biol 26:3319-3326.
39. Porter P, El-Bastawissi A, Mandelson M, Lin M, Khalid N, Watney E, Cousens L, White D, Taplin S, White J. 1999. Breast tumor characteristics as predictors of mammographic detection: Comparison of Interval-and screen-detected cancers. J Natl Cancer Inst 91:2020-2028.
40. Rai R, Dai H, Multani A, Li K, Chin K, Gray J, Lahad J, Liang J, Mills G, Meric-Bernstam F, Lin S. 2006. BRIT1 regulates early DNA damage response, chromosomal integrity, and cancer. Cancer Cell 10:145-157.
41. Ramos D, Aldaz C. 2006. WWOX, a chromosomal fragile site gene and its role in cancer. Adv Exp Med Biol 587:149-159.
42. Roylance R, Gorman P, Harris W, Leibmann R, Barnes D, Hanby A, Sheer D. 1999. Comparative genomic hybridization of breast tumors stratified by histological grade reveals new insights into the biological progression of breast cancer. Cancer Res 59:1433-1436.
43. Roylance R, Gorman P, Papior T, Wan Y, Ives M, Watson J, Collins C, Wortham N, Langford C, Fiegler H, Carter N, Gillett C, Sasieni P, Pinder S, Hanby A, Tomlinson I. 2006. A comprehensive study of chromosome 16q in invasive ductal and lobular breast carcinoma using array CGH. Oncogene 25:6544-6553.
44. Taylor C, Shi S-R, Chaiwun B, Young L, Imam S, Cote R. 1994. Strategies for improving the immunohistochemical staining of various intranuclear prognostic markers in formalin-paraffin sections: Androgen receptor, estrogen receptor, progesterone receptor, p53 protein, proliferating cell nuclear antigen and Ki-67 antigen revealed by antigen retrieval techniques. Hum Pathol 25:263-270.
45. Thompson E, Herbert S, Forrest S, Campbell I. 2005. Whole genome SNP arrays using DNA derived from formalin-fixed, paraf-fin-embedded ovarian tumor tissue. Hum Mutat 26:384-389.
46. Tomlinson I, Nicolai H, Solomon E, Bodmer W. 1996. The frequency and mechanism of loss of heterozygosity on chromosome 11q in breast cancer. J Pathol 180:38-43.
47. Wang Z, Lin M, Wei L-J, Li CI, Miron A, Lodeiro G, Harris L, Ramaswa y, S, Tanenbaum D, Meyerson M, Iglehart J, Richardson A. 2004. Loss of heterozygosity and its correlation with expression profiles in subclasses of invasive breast cancer. Cancer Res 64:64-71.
48. Women's Health Initiative Steering Committee. 2004. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: The Women's Health Initiative randomized controlled trial. JAMA 291:1701-1712.
49. Xu L, Begum S, Hearn J, Hynes R. 2006. GPR56, an atypical G protein-coupled receptor, binds tissue transglutaminase, TG2, and inhibits melanoma tumor growth and metastasis. Proc Natl Acad Sci USA 103:9023-9028.
50. Xu X, Lee J, Stern D. 2004. Microcephalin is a DNA damage response protein involved in regulation of CHK1 and BRCA1. J Biol Chem 279:34091-34094.
51. Zhao H, Langerod A, Ji Y, Nowels K, Nesland J, Tibshirani R, Bukholm I, Karesen R, Botstein D, Borresen-Dale A, Jeffrey S. 2004. Different gene expression patterns in invasive lobular and ductal carcinomas of the breast. Mol Biol Cell 15:2523-2536.